Quantcast

Latest Novocure Limited Stories

2014-07-15 08:28:10

Physicians at 15 leading brain cancer centers in 8 countries certified to provide NovoTTF Therapy to recurrent glioblastoma patients on prescription order LUCERNE, Switzerland, July 15, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that 18 prominent neurosurgeons and neuro-oncologists at medical centers in Europe and Israel are trained and certified to prescribe NovoTTF Therapy. These physicians will now be able to treat recurrent glioblastoma...

2014-06-13 08:23:58

Analysis of PRiDe, a U.S. commercial registry of 457 recurrent glioblastoma patients, demonstrates that patients treated with NovoTTF Therapy at their first recurrence achieved a median overall survival of 20 months NEW YORK, June 13, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that subgroup survival data from its U.S. commercial patient registry will be presented at the 16(th) Biennial Canadian Neuro-Oncology Meeting in Halifax, Nova Scotia,...

2014-05-19 08:28:02

A registry of 457 recurrent glioblastoma patients shows that patients treated commercially with NovoTTF Therapy in 2012 and 2013 achieved the longest median overall survival yet shown in non-experimental use for patients with recurrent glioblastoma NEW YORK, May 19, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that an analysis of the efficacy and safety data from its U.S. patient registry will be published as part of the 50(th) meeting of the...

2014-04-03 12:29:26

HAIFA, Israel, April 3, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that new, pre-clinical data demonstrating the anti-tumor effects of NovoTTF(TM) Therapy will be presented at the 2014 American Association for Cancer Research (AACR) in San Diego (April 5-9, 2014). The new study results show that ovarian cancer cells treated with Tumor Treating Fields (TTFields) exhibit abnormal chromosomal separation during cell division, reducing the viability of...

2014-02-18 08:32:26

The NovoTAL System Enables Certified Physicians to Plan and Individualize NovoTTF(TM) Therapy for Recurrent Glioblastoma Patients NEW YORK, Feb. 18, 2014 /PRNewswire/ -- Novocure announced today that Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center has licensed the NovoTAL (Transducer Array Layout) System. The NovoTAL System allows certified physicians to use a recurrent GBM patient's MRI data to optimize the distribution and intensity of NovoTTF Therapy....

2014-01-24 08:24:33

HAIFA, Israel, Jan. 24, 2014 /PRNewswire/ -- Novocure announced today that the first patient has enrolled in the EF-20 Study, an open label, pilot clinical trial of NovoTTF Therapy plus gemcitabine as first-line therapy for patients with locally advanced and metastatic pancreatic adenocarcinoma. NovoTTF Therapy is an anti-mitotic treatment delivered continuously with a wearable, home-use medical device. "The EF-20 study builds on extensive preclinical research demonstrating the...

2014-01-06 08:27:57

HAIFA, Israel, Jan. 6, 2014 /PRNewswire/ -- Novocure(TM) announced today that the first evidence of activity of NovoTTF Therapy in pancreatic cancer tumor models was published online (December 16(th), 2013) in the prestigious peer reviewed journal Pancreatology. The published study showed that application of NovoTTF Therapy to pancreatic cancer cells in vitro leads to a significant decrease in cell count and reduced ability to form clones. Further analysis demonstrated a significant...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related